Abliva Management
Management criteria checks 2/4
Abliva's CEO is Ellen Donnelly, appointed in Feb 2021, has a tenure of 3.25 years. total yearly compensation is SEK7.03M, comprised of 54.1% salary and 45.9% bonuses, including company stock and options. directly owns 0.03% of the company’s shares, worth SEK62.71K. The average tenure of the management team and the board of directors is 7.5 years and 7.3 years respectively.
Key information
Ellen Donnelly
Chief executive officer
kr7.0m
Total compensation
| CEO salary percentage | 54.1% |
| CEO tenure | 3.3yrs |
| CEO ownership | 0.03% |
| Management average tenure | 7.5yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business
Dec 18
Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation
Aug 24Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Aug 21We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate
Oct 13Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?
Mar 22How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?
Dec 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | kr7m | kr4m | -kr96m |
| Sep 30 2023 | n/a | n/a | -kr88m |
| Jun 30 2023 | n/a | n/a | -kr80m |
| Mar 31 2023 | n/a | n/a | -kr79m |
| Dec 31 2022 | kr6m | kr3m | -kr85m |
| Sep 30 2022 | n/a | n/a | -kr105m |
| Jun 30 2022 | n/a | n/a | -kr114m |
| Mar 31 2022 | n/a | n/a | -kr124m |
| Dec 31 2021 | kr4m | kr2m | -kr123m |
Compensation vs Market: Ellen's total compensation ($USD649.89K) is above average for companies of similar size in the Swedish market ($USD251.23K).
Compensation vs Earnings: Ellen's compensation has increased whilst the company is unprofitable.
CEO
Ellen Donnelly (49 yo)
3.3yrs
Tenure
kr7,029,000
Compensation
Dr. Ellen K. Donnelly, Ph D has been Chief Executive Officer at Abliva AB (publ) since February 03, 2021. She serves as Independent Director at Modus Therapeutics Holding Ab since 2020.Dr. Donnelly has be...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 3.3yrs | kr7.03m | 0.030% SEK 62.7k | |
| Deputy CEO | 10.4yrs | no data | 0.025% SEK 52.7k | |
| Chief Scientific Officer & VP of Discovery | 24.3yrs | kr247.00k | 0.059% SEK 123.1k | |
| Director of Communications | 6.6yrs | no data | no data | |
| Chief Medical Officer and VP of Preclinical & Clinical Development | 8.3yrs | no data | 0.068% SEK 142.7k | |
| Vice President of Clinical Operations | 1.3yrs | no data | 0.0017% SEK 3.6k | |
| Consultant | no data | no data | no data |
7.5yrs
Average Tenure
53yo
Average Age
Experienced Management: ABLI's management team is seasoned and experienced (7.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 8.1yrs | kr1.43m | 0.18% SEK 384.3k | |
| Director | 7.3yrs | kr477.00k | 0.011% SEK 22.8k | |
| Director | 7.3yrs | kr438.00k | 0.0050% SEK 10.5k | |
| Director | 6.1yrs | kr464.00k | no data | |
| Director | 3.8yrs | no data | 19.02% SEK 39.7m |
7.3yrs
Average Tenure
63yo
Average Age
Experienced Board: ABLI's board of directors are considered experienced (7.3 years average tenure).